Devices and methods of screening for neoplastic and inflammatory disease

• US 20060036138A1
• Filed: 08/05/2005
• Published: 02/16/2006
• Est. Priority Date: 08/06/2004
• Status: Abandoned Application

• Current Assignee: Adam Heller
• Original Assignee: Adam Heller
• Inventors: Heller, Adam, Liebermann, Thomas
• Application Number:
  US11/197,872
• Publication Number:
  US 20060036138A1
• Time in Patent Office: Days
• US Class Current: 600/309
• CPC Class Codes: A61B 5/145 Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissuemeasuring of blood pressure or blood flow A61B5/02; non-radiation detecting or locating of foreign bodies in blood A61B5/06
• CPC Class Codes: A61B 5/411 Detecting or monitoring allergy or intolerance reactions to an allergenic agent or substance
• CPC Class Codes: A61B 5/4283 gastrointestinal secretions, e.g. bile production
• CPC Class Codes: A61B 5/4547 Evaluating teeth

Abstract

Methods and devices are provided for evaluating the presence of disease in a patient. In particular, methods and devices are provided for screening patients for neoplastic and/or inflammatory disease. Such diseases are often indicated by the elevated level of a chemical compound associated with disease, such as nitric oxide (NO) and/or nitrogen dioxide (NO₂). Through measuring and/or estimating the chemical compound-concentration, such as by change in fluorescence, absorbance or reflectance, the methods and tools provided distinguish between patients who require further testing and/or treatment and those who do not. The methods and tools also provide information about the effectiveness of treatment, such as treatment to reduce inflammation or control of the growth of malignant tumors. These methods and devices are relatively inexpensive, easy to use, and provide other advantages.

Claims

1. A device for evaluating a suspected diseased tissue of a patient, the device comprising:

at least one reactive material which undergoes a spectral change upon exposure to a pre-determined chemical compound; and

a support structure supporting the at least one reactive material, the support structure being adapted for positioning the at least one reactive material within expected diffusion range of the pre-determined chemical compound from the suspected diseased tissue.

2. A device as in claim 1, wherein the chemical compound is in a gaseous state at 37°

C.

3. A device as in claim 1, wherein the chemical compound comprises nitric oxide and/or nitrogen dioxide.

4. A device as in claim 1, wherein the at least one reactive material comprises an NO-reactive material.

5. A device as in claim 1, wherein the at least one reactive material comprises a color-changing material.

6. A device as in claim 1, wherein the at least one reactive material comprises a luminescence-changing material.

7. A device as in claim 1, wherein the at least one reactive material is incorporated within the support structure.

8. A device as in claim 6, wherein the support structure comprises plastic having the at least one reactive material incorporated therein.

9. A device as in claim 1, wherein the at least one reactive material is attached to an external surface of the support structure.

10. A device as in claim 1, further comprising an external covering having the at least one reactive material, wherein the external covering covers at least a portion of the support structure.

11. A device as in claim 10, wherein the external covering comprises a coating, sheath or sleeve.

12. A device as in claim 1, wherein the support structure comprises a probe having an elongate tip adapted for insertion into an orifice of the patient leading to the suspected diseased tissue.

13. A device as in claim 12, wherein the tip is adapted for insertion into an anus and positioning of the at least one reactive material in a rectum, colon, small intestine or large intestine.

14. A device as in claim 12, wherein the tip is adapted for insertion into a mouth and positioning of the at least one reactive material in an upper respiratory tract, esophagus or stomach.

15. A device as in claim 12, wherein the tip is adapted for insertion into the mouth and positioning of the at least one reactive material near a tooth or between two teeth.

16. A device as in claim 1, wherein the support structure comprises a tethered body having a retrieving element, wherein the tethered body is adapted for positioning within the patient.

17. A device as in claim 16, wherein the tethered body comprises a plug configured for insertion within a rectum or vagina.

18. A device as in claim 16, wherein the tethered body comprises a gastric capsule configured for insertion within a stomach.

19. A device as in claim 1, wherein the support structure comprises at least one bead swallowable by the patient.

20. A device as in claim 19, wherein each bead has a magnetic core.

21. A device as in claim 1, wherein the support structure comprises a sheet adapted for positioning against a surface of the suspected diseased tissue.

22. A device as in claim 21, wherein the surface comprises skin of the patient.

23. A device as in claim 1, further comprising an external covering adapted for covering the at least one reactive material, wherein the external covering reduces leaching of the at least one reactive material.

24. A device as in claim 1, wherein the reactive material includes an energy transferring material.

25. A method of evaluating a suspected diseased tissue of a patient, the method comprising:

positioning a reactive material within an expected diffusion range of a pre-determined chemical compound from the suspected diseased tissue of the patient, wherein the reactive material is able to undergo a spectral change upon exposure to the pre-determined chemical compound;

observing the spectral change or an absence of the spectral change;

evaluating the suspected diseased tissue based on the observing step.

26. A method as in claim 25, wherein in response to observing the spectral change the method further comprises comparing the spectral change to a calibration to quantify the spectral change.

27. A method as in claim 25, wherein in response to observing the spectral change the method further comprises measuring the spectral change with an instrument.

28. A method as in claim 25, wherein the chemical compound comprises nitric oxide and/or nitrogen dioxide.

29. A method as in claim 25, wherein the reactive material comprises a color-changing material and wherein observing comprises determining a change in color or determining a lack of change in color.

30. A method as in claim 25, wherein the reactive material comprises a luminescence-changing material and wherein observing comprises determining a change in luminescence or a lack of change in luminescence.

31. A method as in claim 25, wherein positioning comprises inserting the reactive material into an orifice of the patient leading to the suspected diseased tissue.

32. A method as in claim 31, wherein inserting comprises inserting the reactive material into an anus.

33. A method as in claim 32, further comprising advancing the reactive material to a rectum, colon, small intestine or large intestine.

34. A method as in claim 31, wherein inserting comprises inserting the reactive material into a mouth.

35. A method as in claim 34, further comprising advancing the reactive material to an upper respiratory tract, esophagus or stomach.

36. A method as in claim 25, wherein the reactive material is supported by a support structure and wherein positioning comprises positioning the support structure near the suspected diseased tissue.

37. A method as in claim 36, wherein the support structure comprises a probe having an elongate tip carrying the reactive material and positioning comprises positioning the elongate tip near the suspected diseased tissue.

38. A method as in claim 36, wherein the support structure comprises a plug and positioning comprises positioning the plug within a rectum or vagina.

39. A method as in claim 36, wherein the support structure comprises a gastric capsule and positioning comprises positioning the capsule within a stomach.

40. A method as in claim 36, wherein the support structure comprises a bead and positioning comprises swallowing the bead.

41. A method as in claim 36, wherein the support structure comprises a sheet and positioning comprises positioning the sheet against a surface of the suspected diseased tissue.

42. A method as in claim 41, wherein the surface comprises skin of the patient.